Equities

Mizuho Medy Co Ltd

4595:TYO

Mizuho Medy Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (JPY)1,735.00
  • Today's Change6.00 / 0.35%
  • Shares traded70.90k
  • 1 Year change+61.02%
  • Beta1.9411
Data delayed at least 20 minutes, as of Jul 25 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MIZUHO MEDY CO., LTD. is a Japan-based company principally engaged in-vitro diagnostic pharmaceuticals business. The Company mainly provides in-vitro diagnostic pharmaceuticals, including immune serum test drugs, biochemical test drugs, urine and feces test drugs, microbial test drugs, blood test drugs, pathological test drugs and others, in hospital and medical practitioner fields. In addition, the Company also provides over-the-counter (OTC) drugs to pharmacies and drug stores, and sells fruit tree virus test drugs to which they apply the technology of immune serology test to agricultural test centers.

  • Revenue in JPY (TTM)11.34bn
  • Net income in JPY4.00bn
  • Incorporated1977
  • Employees180.00
  • Location
    Mizuho Medy Co Ltd5-4, Fujinoki-machiTOSU-SHI 841-0048JapanJPN
  • Phone+81 942850303
  • Fax+81 942850312
  • Websitehttps://www.mizuho-m.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Seed Co Ltd32.40bn1.96bn17.01bn962.007.300.983.550.52576.9476.941,276.55573.500.72332.657.4833,676,460.004.381.997.533.5143.7842.316.062.740.8037--0.578139.565.891.90721.4415.3020.424.56
Daiken Medical Co Ltd9.75bn988.60m17.23bn175.0015.722.2114.321.7734.4134.41339.39244.440.88563.914.0355,715,240.008.987.4412.9110.8440.8441.7410.149.281.58752.550.231571.356.713.0138.843.03-4.010.9806
Japan Medical Dynamic Marketing, INC.23.18bn1.27bn17.63bn511.0013.790.68756.080.760848.3048.30880.53968.740.76090.68154.1545,357,630.004.296.514.927.5363.6966.975.638.882.11--0.055218.338.786.74-10.68-8.52-2.959.24
Medius Holdings Co Ltd250.78bn847.94m19.05bn2.29k22.330.95877.330.07638.5138.5111,407.31897.032.2717.994.25109,607,600.000.76731.643.176.0212.0511.490.33810.58370.899338.740.565731.155.497.29-19.8015.0942.529.46
Medical Data Vision Co Ltd6.25bn688.02m21.65bn262.0030.045.1928.643.4718.0118.01163.57104.341.15282.077.8423,847,790.0012.1816.1617.0120.8877.4381.9010.5515.522.7213.480.0019.985.1512.4012.4869.75-23.95--
Findex Inc6.06bn1.50bn27.97bn290.0017.945.1315.824.6158.5958.59236.49204.981.066.593.3420,912,110.0026.1915.7230.2418.4165.2456.8124.7814.585.62--0.0036.2014.327.5846.5421.62-3.3411.63
Japan Tissue Engineering Co., Ltd.2.51bn143.17m28.43bn211.00198.564.68102.5411.313.533.5361.91149.730.36253.534.2611,915,590.002.06-4.722.37-5.3167.2457.305.69-16.385.85996.590.00--23.701.29119.63--30.22--
Nippon Care Supply Co., Ltd.28.59bn1.58bn32.17bn1.33k19.501.864.161.13101.57101.571,840.191,064.291.18126.0522.9121,433,730.006.507.618.919.9435.8537.585.526.780.7568--0.075956.7510.4310.474.212.0724.048.76
Mizuho Medy Co Ltd11.34bn4.00bn32.94bn180.008.242.157.862.90209.87209.87595.31803.890.64841.872.9962,999,830.0022.8631.4626.2339.7873.4174.8535.2533.646.41--0.0034.83-37.4911.34-51.8532.64-17.7432.85
Rion Co Ltd25.73bn2.65bn33.41bn1.03k12.571.149.401.30215.52215.522,090.442,372.880.71771.863.4625,075,050.007.406.278.627.2550.7150.2910.318.852.53--0.000828.117.793.8647.395.7825.244.56
Win-Partners Co Ltd77.06bn1.84bn36.85bn629.0018.771.4818.140.478264.3764.372,703.63818.751.6824.494.07122,518,600.004.014.397.558.0612.3712.502.382.681.71--0.0063.188.762.01-10.33-7.0140.619.34
France Bed Holdings Co Ltd59.15bn3.13bn45.81bn1.78k13.751.085.240.774486.7886.781,639.201,106.360.88783.245.8033,174,990.004.703.856.185.2453.9152.365.304.411.90--0.324149.980.97822.7015.993.81-1.019.30
TAUNS Laboratories Inc-100.00bn-100.00bn47.50bn272.00--3.44----------137.95------------------------1.04--0.334---10.22---32.27------
Data as of Jul 25 2024. Currency figures normalised to Mizuho Medy Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

1.94%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 04 Jul 2024116.20k0.61%
Mellon Investments Corp.as of 03 Jul 202495.10k0.50%
American Century Investment Management, Inc.as of 03 Jul 202472.00k0.38%
BlackRock Fund Advisorsas of 03 Jul 202433.00k0.17%
Mitsubishi UFJ Asset Management Co., Ltd.as of 27 Feb 202316.00k0.08%
Lazard Asset Management LLCas of 31 Dec 202312.80k0.07%
Asset Management One Co., Ltd.as of 04 Jul 20247.50k0.04%
Dimensional Fund Advisors Ltd.as of 04 Jul 20247.21k0.04%
Victory Capital Management, Inc. (Investment Management)as of 31 Mar 20245.60k0.03%
DFA Australia Ltd.as of 31 May 20244.99k0.03%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.